IP Library › Granted Patent US 10,561,703
Granted Patent B2
US 10,561,703 · App. 14/899,746 · Granted Feb 18, 2020

Method of modulating sex hormone levels using a sex hormone secretion modulator

Inventor: Sang Jae Kim (Seoul, KR)
Assignee: GemVaX & KAEL Co., Ltd.
A61K38/10A61K39/39A61K38/45C07K7/08C07K14/575C12N9/1276C12Y207/07049
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,561,703
App. No.
14/899,746
Granted
Feb 18, 2020
Kind
B2
Abstract

Provided are a hormone secretion modulator including a peptide derived from telomerase, more particularly, a peptide including an amino acid sequence of SEQ ID NO: 1, an amino acid sequence having a sequence identity of at least 80% with SEQ ID NO: 1, or a fragment thereof, a pharmaceutical composition including the hormone secretion modulator, and a use of the pharmaceutical composition for treatment, alleviation, or prevention of diseases caused by excessive or deficient levels hormones.

Claims (20)

1. A method of increasing testosterone level in a male subject, or increasing follicle stimulating hormone (FSH), luteinizing hormone (LH), or gonadotropin-releasing hormone (GnRH) levels in a male or a female subject comprising administering to the subject an effective amount of the peptide of SEQ ID NO: 1.

2. The method of claim 1 , wherein the administration is once a day.

3. The method of claim 1 , wherein the administration is one to three times a day.

4. The method of claim 1 , further comprising administering to the subject an adjuvant.

5. The method of claim 4 , wherein the adjuvant is a granulocyte-macrophage colony-stimulating factor (GM-CSF).

6. The method of claim 5 , wherein GM-CSF is administered at a dosage of about 7 mg to about 700 mg.

7. The method of claim 5 , wherein GM-CSF is subcutaneously administered at about 1 minute to about 150 minutes before the administration of the peptide.

8. The method of claim 5 , wherein GM-CSF is subcutaneously administered at about 5 minutes to about 80 minutes before the administration of the peptide.

9. The method of claim 5 , wherein GM-CSF is subcutaneously administered at about 10 minutes to about 15 minutes before the administration of the peptide.

10. The method of claim 1 , wherein the subject is selected from a group consisting of humans, dogs, chickens, pigs, cows, sheep, guinea pigs, and monkeys.

11. The method of claim 1 , wherein the peptide of SEQ ID NO: 1 is administered through oral, rectal, transdermal, intravenous, intramuscular, intraperitoneal, intramedullary, epidural, or subcutaneous means.

12. The method of claim 1 , wherein the peptide of SEQ ID NO: 1 is administered through the oral means.

13. The method of claim 12 , wherein the peptide of SEQ ID NO: 1 is administered as tablets, pills, soft or hard capsules, granules, powders, solutions, or emulsions.

14. The method of claim 1 , wherein the peptide of SEQ ID NO: 1 is administered as injections, drips, lotions, ointments, gels, creams, suspensions, emulsions, suppositories, patches, or sprays.

15. The method of claim 1 , wherein the peptide of SEQ ID NO: 1 is administered at a dosage of about 0.1 μg/kg/day to about 1 g/kg/day.

16. The method of claim 1 , wherein the peptide of SEQ ID NO: 1 is administered at a dosage of about 1 μg/kg/day to about 10 mg/kg/day.

17. The method of claim 1 , wherein the peptide of SEQ ID NO: 1 is administered at a dosage of about 10 μg/kg/day to about 1 mg/kg/day.

18. The method of claim 1 , wherein the peptide of SEQ ID NO: 1 is administered at a dosage of about 50 μg/kg/day to about 100 μg/kg/day.

19. A method of increasing testosterone level in a male subject comprising administering to the subject an effective amount of the peptide of SEQ ID NO: 1.

20. A method of increasing follicle stimulating hormone (FSH), luteinizing hormone (LH), or gonadotropin-releasing hormone (GnRH) levels in a male or a female subject comprising administering to the subject an effective amount of the peptide of SEQ ID NO: 1.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2023
From: GEMVAX & KAEL CO. LTD.
To: GEMVAX & KAEL CO. LTD.; KIM, SANG JAE
Reel/Frame 065471/0754 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2015
From: KIM, SANG JAE
To: GEMVAX & KAEL CO., LTD
Reel/Frame 037375/0333 →
Priority Claims (1)
EP 13173219 · Jun 21, 2013 · regional
Continuity (1)
Related Publication 20160137695A1 · May 19, 2016